Literature DB >> 32030294

For radiation therapy before surgery in esophageal cancer, dose matters, and with each answer comes more questions.

Mark Hennon1, Sai Yendamuri1.   

Abstract

Entities:  

Year:  2019        PMID: 32030294      PMCID: PMC6987982          DOI: 10.21037/jtd.2019.12.62

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  6 in total

1.  No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.

Authors:  Eisar Al-Sukhni; Emmanuel Gabriel; Kristopher Attwood; Moshim Kukar; Steven J Nurkin; Steven N Hochwald
Journal:  J Am Coll Surg       Date:  2016-09-15       Impact factor: 6.113

2.  Radiation With Neoadjuvant Chemotherapy Does Not Improve Outcomes in Esophageal Squamous Cell Cancer.

Authors:  James A Miller; Adrienne Groman; Sai Yendamuri; Mark Hennon
Journal:  J Surg Res       Date:  2018-12-24       Impact factor: 2.192

3.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Authors:  Joel Shapiro; J Jan B van Lanschot; Maarten C C M Hulshof; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R C Busch; Fiebo J W Ten Kate; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Herman van Dekken; Maurice J C van der Sangen; Tom Rozema; Katharina Biermann; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast
Journal:  Lancet Oncol       Date:  2015-08-05       Impact factor: 41.316

4.  Induction Radiation Therapy for Esophageal Cancer: Does Dose Affect Outcomes?

Authors:  Tara R Semenkovich; Pamela P Samson; Jessica L Hudson; Melanie Subramanian; Bryan F Meyers; Benjamin D Kozower; Daniel Kreisel; G Alexander Patterson; Clifford G Robinson; Jeffrey D Bradley; Varun Puri
Journal:  Ann Thorac Surg       Date:  2018-11-13       Impact factor: 4.330

5.  Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.

Authors:  Michael Stahl; Martin K Walz; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Jorge Riera-Knorrenschild; Peter Langer; Rita Engenhart-Cabillic; Michael Bitzer; Alfred Königsrainer; Wilfried Budach; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

6.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.